Neoadjuvant Sintilimab with Chemotherapy for Esophageal Cancer
Author Information
Author(s): Cai Haibo, Chen Liji, Huang Junjun, Ma Hongmei, Zhang Shifa, Zhong Kaize, Yang Dongbao, Sun Jiuhe, Liu Hongfeng, Song Ru
Primary Institution: Jining No. 1 People’s Hospital, Jining, Shandong, China
Hypothesis
Can neoadjuvant immunotherapy combined with chemotherapy improve survival for patients with locally advanced resectable esophageal squamous cell carcinoma?
Conclusion
Neoadjuvant sintilimab combined with chemotherapy shows promising efficacy and safety for treating locally advanced resectable esophageal squamous cell carcinoma.
Supporting Evidence
- The two-year overall survival rate for the neoadjuvant immunochemotherapy group was 91.5%, compared to 71.2% for the surgery-only group.
- Patients in the neoadjuvant immunochemotherapy group had a major pathological response rate of 61.7%.
- Adverse events related to treatment were mostly manageable and of low severity.
Takeaway
This study looked at whether a new treatment combining immunotherapy and chemotherapy helps people with a type of esophageal cancer live longer and healthier after surgery.
Methodology
A retrospective analysis of 120 patients with locally advanced resectable esophageal squamous cell carcinoma who underwent surgery, comparing outcomes between those receiving neoadjuvant immunochemotherapy and those receiving surgery alone.
Limitations
The study was conducted at a single center and did not explore relevant tumor markers that may affect treatment outcomes.
Participant Demographics
Patients were predominantly male (around 72%) with a median age of 66 years.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website